KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.

Kenneth I Berger, Cristina Ivanescu, Jérôme Msihid, Magali Periquet, Alaa Hamed, Kristina An Haack, Tianyue Zhou, Nadine van der Beek, Matthias Boentert, Ruth Pulikottil-Jacob, Laurence Pollissard

J Neuromuscul Dis 12(4) 523-534

PMID40397025
PMCIDPMC13142852
DOI10.1177/22143602251332829
发表日期2025-05-21
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 forest plot;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

BackgroundRespiratory impairment in neuromuscular disorders (NMDs) is generally assessed using forced vital capacity (FVC). Any improvement in FVC trajectory will delay ventilatory support; however, the change required for patients to perceive a noticeable clinical benefit, the clinically meaningful threshold (CMT), has not been defined in NMDs.ObjectiveTo derive the within-person and between-group CMTs for FVC (% predicted) in patients with late-onset Pompe disease (LOPD).MethodsThis analysis leverages data from the Phase 3 COMET trial (NCT02782741, registered 25 May 2016), which assessed the efficacy of avalglucosidase alfa (AVA) versus alglucosidase alfa (ALG) on upright FVC (% predicted) in LOPD. Anchor- and distribution-based methods were used to estimate the within-person and between-group CMTs for FVC at Weeks 49 and 97.ResultsCOMET enrolled 99 participants aged ≥18 years (52% male; mean age 48.0 years). The within-person CMT for absolute change in FVC expressed as % predicted was estimated as 3.0% [95% confidence interval (CI) 2.3, 3.8]. The proportion of patients with a meaningful increase in FVC was higher in the AVA versus ALG group across the CI of the estimated CMT (odds ratios: 2.3-2.6; nominal p-values: 0.026-0.058). The between-group CMT, needed to evaluate differences between treatment groups, was estimated as 2.1% predicted [95% CI 1.1, 3.1].ConclusionsWe identified a narrow range of within-person and between-group CMTs for upright FVC (% predicted) in LOPD. Post hoc application of these thresholds to COMET showed that a greater proportion of patients in the AVA group had clinically meaningful improvement in FVC versus ALG. These findings may aid in interpretation of data from studies in other NMDs.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Results of the a. within-person and b. between-group CMT estimates for absolute change in FVC (% predicted): anchor-based analyses and distribution-based analyses. *Estimates from the distribution-based approach were not included in the weighted estimate for the within-person CMT. Distribution-based estimate is represented as an orange square. Anchor-based individual estimates are represented as black circles. Correlation-weighted estimates are represented in blue diamonds along with their 95% CI and considered only those anchors with r ≥ 0.25 at Week 49 or Week 97. CI, confidence interval; CMT, clinically meaningful threshold; FVC, forced vital capacity; PCS, physical component score; PDIS, Pompe Disease Impact Scale; PGIC, Patient Global Impression of Change; r, correlation; SD, standard deviation; SEM, standard error of the mean; SF-12v2, 12-item Short-Form (version 2) Health survey
非 KM Figure
Figure 2Figure 2. Patients with a meaningful change from baseline to Week 49 in upright FVC (% predicted). OR [95% CI] are presented. OR values larger than 1.0 represent better odds for AVA compared with ALG. ALG, alglucosidase alfa; AVA, avalglucosidase alfa; CI, confidence interval; FVC, forced vital capacity; OR, odds ratio
非 KM Figure
Figure 3Figure 3. Empirical cumulative distribution function of absolute change in upright FVC (% predicted) from baseline to Week 49 by treatment groups. Only patients with non-missing change from baseline are included in this graph. ALG, alglucosidase alfa; AVA, avalglucosidase alfa; CMT, clinically meaningful threshold; FVC, forced vital capacity
非 KM Figure